Last edition
News about "CLARITY-Gastric01 Phase 3 Trial"
AstraZeneca's Sonesitatug Vedotin Cuts Death Risk by 42 Percent
AstraZeneca’s sonesitatug vedotin cuts death risk by 42 percent in advanced CLDN18.2-positive gastric cancer, with a 53 percent reduction in later-line treatment.
CLARITY-Gastric01 Phase 3 Trial | 26/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members